MX385972B - Partículas y composiciones de nicotina. - Google Patents
Partículas y composiciones de nicotina.Info
- Publication number
- MX385972B MX385972B MX2018015118A MX2018015118A MX385972B MX 385972 B MX385972 B MX 385972B MX 2018015118 A MX2018015118 A MX 2018015118A MX 2018015118 A MX2018015118 A MX 2018015118A MX 385972 B MX385972 B MX 385972B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- nicotine particles
- particles
- nicotine
- sugar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177163 | 2016-06-30 | ||
| PCT/IB2017/053543 WO2018002756A1 (en) | 2016-06-30 | 2017-06-14 | Nicotine particles and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015118A MX2018015118A (es) | 2019-04-15 |
| MX385972B true MX385972B (es) | 2025-03-18 |
Family
ID=56296661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015118A MX385972B (es) | 2016-06-30 | 2017-06-14 | Partículas y composiciones de nicotina. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20190133940A1 (https=) |
| EP (1) | EP3478264B1 (https=) |
| JP (2) | JP2019524648A (https=) |
| KR (1) | KR102523677B1 (https=) |
| CN (1) | CN109310622A (https=) |
| AR (1) | AR108920A1 (https=) |
| AU (1) | AU2017286864A1 (https=) |
| CA (1) | CA3023630A1 (https=) |
| ES (1) | ES3055891T3 (https=) |
| IL (1) | IL263355A (https=) |
| MX (1) | MX385972B (https=) |
| PH (1) | PH12018502714A1 (https=) |
| PL (1) | PL3478264T3 (https=) |
| RU (1) | RU2767064C2 (https=) |
| SG (1) | SG11201809594WA (https=) |
| TW (1) | TW201801716A (https=) |
| UA (1) | UA124535C2 (https=) |
| WO (1) | WO2018002756A1 (https=) |
| ZA (1) | ZA201806949B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3055891T3 (en) * | 2016-06-30 | 2026-02-16 | Philip Morris Products Sa | Nicotine particles and compositions |
| WO2020071448A1 (ja) * | 2018-10-02 | 2020-04-09 | 学校法人名城大学 | 吸入粉末剤、その評価方法及びその用途 |
| EP3946262B1 (en) * | 2019-08-30 | 2024-07-31 | Evie Sa | Loaded granules, their process of production and their uses |
| CN110384700A (zh) * | 2019-09-03 | 2019-10-29 | 云南喜科科技有限公司 | 一种合成尼古丁的组合物 |
| UA130281C2 (uk) | 2019-11-14 | 2026-01-07 | Філіп Морріс Продактс С.А. | Сухий порошковий склад зі смаком тютюну, спосіб його одержання та порошкова система |
| KR20220119101A (ko) | 2019-12-19 | 2022-08-26 | 쥴 랩스, 인크. | 유기 기반 니코틴 겔 조성물 |
| EP4076026A1 (en) | 2019-12-19 | 2022-10-26 | Juul Labs, Inc. | Metal oxide-based gel nicotine compositions |
| CA3164639A1 (en) | 2019-12-20 | 2021-06-24 | Juul Labs, Inc. | Hydrated ionic clay and tobacco material compositions |
| WO2021201258A1 (ja) * | 2020-04-01 | 2021-10-07 | 株式会社ＳｔａｔｅＡｒｔ | 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法 |
| ES3040112T3 (en) * | 2020-06-15 | 2025-10-28 | Philip Morris Products Sa | Anatabine powder compositions |
| BR112023003114A2 (pt) * | 2020-09-03 | 2023-04-04 | Philip Morris Products Sa | Composições em pó ativas de baixa higroscopicidade liofilizadas |
| WO2022049488A1 (en) * | 2020-09-03 | 2022-03-10 | Philip Morris Products S.A. | Spray dried low hygroscopicity active powder compositions |
| US12594238B2 (en) * | 2020-09-03 | 2026-04-07 | Philip Morris Products S.A. | Low hygroscopicity active powder compositions |
| USD1081739S1 (en) | 2021-04-06 | 2025-07-01 | Altria Client Services Llc | Die for gum forming |
| US20220313678A1 (en) * | 2021-04-06 | 2022-10-06 | Altria Client Services Llc | Spray dried nicotine for inclusion in oral products |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2231968A1 (en) * | 1998-03-11 | 1999-09-11 | Smoke-Stop, A Partnership Consisting Of Art Slutsky | Method of producing a nicotine medicament |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| JP2001151673A (ja) * | 1999-09-06 | 2001-06-05 | Nikken Chem Co Ltd | 吸入用粉末製剤の製造方法 |
| NZ518401A (en) * | 1999-10-29 | 2004-01-30 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
| SK11142002A3 (sk) * | 1999-12-30 | 2004-09-08 | Chiron Corporation | Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2 |
| CA2418960A1 (en) * | 2000-08-07 | 2002-02-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
| US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| MX2007004495A (es) * | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina. |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| FI20060428A7 (fi) * | 2006-05-03 | 2007-11-04 | Esko Kauppinen | Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia |
| US20080286340A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered nicotine containing products |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| CA2944471C (en) * | 2014-04-08 | 2020-03-31 | Philip Morris Products S.A. | Nicotine formulations and methods of making the same |
| CA2943746C (en) * | 2014-04-28 | 2023-08-15 | Philip Morris Products S.A. | Flavoured nicotine powder inhaler |
| US10149844B2 (en) * | 2015-09-16 | 2018-12-11 | Philip Morris Products S.A. | Inhalable nicotine formulations, and methods of making and using thereof |
| US9585835B1 (en) * | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
| US11224594B2 (en) * | 2015-09-16 | 2022-01-18 | Philip Morris Products S.A. | Nicotine formulations and methods of making and using the same |
| ES3055891T3 (en) * | 2016-06-30 | 2026-02-16 | Philip Morris Products Sa | Nicotine particles and compositions |
| PL3478265T3 (pl) * | 2016-06-30 | 2025-04-14 | Philip Morris Products S.A. | Cząstki nikotyny |
| IL269275B2 (en) * | 2017-06-28 | 2023-04-01 | Philip Morris Products Sa | Container with particles for use with an inhaler |
-
2017
- 2017-06-14 ES ES17732583T patent/ES3055891T3/es active Active
- 2017-06-14 CA CA3023630A patent/CA3023630A1/en not_active Abandoned
- 2017-06-14 WO PCT/IB2017/053543 patent/WO2018002756A1/en not_active Ceased
- 2017-06-14 CN CN201780034796.4A patent/CN109310622A/zh active Pending
- 2017-06-14 AU AU2017286864A patent/AU2017286864A1/en not_active Abandoned
- 2017-06-14 RU RU2018145313A patent/RU2767064C2/ru active
- 2017-06-14 PL PL17732583.4T patent/PL3478264T3/pl unknown
- 2017-06-14 KR KR1020187035098A patent/KR102523677B1/ko active Active
- 2017-06-14 JP JP2018563781A patent/JP2019524648A/ja active Pending
- 2017-06-14 SG SG11201809594WA patent/SG11201809594WA/en unknown
- 2017-06-14 UA UAA201810794A patent/UA124535C2/uk unknown
- 2017-06-14 US US16/309,742 patent/US20190133940A1/en not_active Abandoned
- 2017-06-14 MX MX2018015118A patent/MX385972B/es unknown
- 2017-06-14 EP EP17732583.4A patent/EP3478264B1/en active Active
- 2017-06-29 TW TW106121799A patent/TW201801716A/zh unknown
- 2017-06-29 AR ARP170101809A patent/AR108920A1/es unknown
-
2018
- 2018-10-18 ZA ZA2018/06949A patent/ZA201806949B/en unknown
- 2018-11-28 IL IL263355A patent/IL263355A/en unknown
- 2018-12-21 PH PH12018502714A patent/PH12018502714A1/en unknown
-
2021
- 2021-08-05 US US17/394,623 patent/US20210361567A1/en not_active Abandoned
-
2022
- 2022-03-02 JP JP2022031716A patent/JP2022071106A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017286864A1 (en) | 2018-11-15 |
| IL263355A (en) | 2018-12-31 |
| ZA201806949B (en) | 2019-07-31 |
| JP2019524648A (ja) | 2019-09-05 |
| AR108920A1 (es) | 2018-10-10 |
| RU2018145313A (ru) | 2020-07-30 |
| EP3478264C0 (en) | 2025-11-19 |
| CA3023630A1 (en) | 2018-01-04 |
| MX2018015118A (es) | 2019-04-15 |
| RU2767064C2 (ru) | 2022-03-16 |
| EP3478264A1 (en) | 2019-05-08 |
| RU2021132299A (ru) | 2021-12-10 |
| ES3055891T3 (en) | 2026-02-16 |
| SG11201809594WA (en) | 2018-11-29 |
| TW201801716A (zh) | 2018-01-16 |
| KR102523677B1 (ko) | 2023-04-20 |
| US20210361567A1 (en) | 2021-11-25 |
| PH12018502714A1 (en) | 2019-07-29 |
| PL3478264T3 (pl) | 2026-02-02 |
| UA124535C2 (uk) | 2021-10-05 |
| JP2022071106A (ja) | 2022-05-13 |
| WO2018002756A1 (en) | 2018-01-04 |
| EP3478264B1 (en) | 2025-11-19 |
| US20190133940A1 (en) | 2019-05-09 |
| CN109310622A (zh) | 2019-02-05 |
| KR20190025824A (ko) | 2019-03-12 |
| RU2018145313A3 (https=) | 2020-07-30 |
| BR112018076215A2 (pt) | 2019-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385972B (es) | Partículas y composiciones de nicotina. | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| WO2018069500A3 (en) | Anti-lag-3 antibodies and compositions | |
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| UA124919C2 (uk) | Швидкодіючі композиції інсуліну | |
| MX2019001313A (es) | Composiciones farmaceuticas. | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| EP3413885A4 (en) | COMPOSITIONS WITH TUCARESOL OR ITS ANALOG | |
| EP3522882A4 (en) | AMINO ACID COMPOSITIONS AND USES THEREOF | |
| MX2018008424A (es) | Compuestos antiproliferativos y sus composiciones farmaceuticas y usos. | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| MX377774B (es) | Formulaciones de proteinas. | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| MX2019002057A (es) | Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. | |
| MX393600B (es) | Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). | |
| MX2019005855A (es) | Formulaciones que se pueden pulverizar. | |
| JOP20200323A1 (ar) | طرق لتصنيع تركيبات الأحماض الأمينية | |
| TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
| EP3677262A4 (en) | KAEMPFEROL ANALOGUE COMPOSITION | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина | |
| EA201791716A1 (ru) | Фармацевтический состав |